Kaplan-Meier (KM) curves for all-cause death rates, macrovascular event rates and T2DM-related hospitalizations for patients with either MET or SU monotherapy (PS matched groups). The figure shows KM curves representing the percentage of event-free patients (all-cause event as well as mortality, MACE and T2DM-related hospitalizations) for two T2DM-incident cohorts: patients who received SU monotherapy and patients who received MET monotherapy. Cohorts are matched by PSM. Observation started with the first observed SU/MET prescription. (TIF 546 kb
Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 5: Figure S3. Risk for cardiovascular and kidney outcome in SGLT2i initiators compar...
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival...
Kaplan-Meier (KM) curves for crude all-cause death rates, macrovascular event rates and T2DM-related...
Kaplan-Meier (KM) curves for crude all-cause death rates, macrovascular event rates and T2DM-related...
Distribution of propensity scores as calculated by logistic regression for MET/SU monotherapy users....
Multivariable Cox regression models estimating time to event for four outcome categories (MET/SU mon...
Additional file 1: Table S1. Descriptive statistics for each drug and dose amount at index date in e...
Additional file 6: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Flow diagram of participants. Chart showing the number of participants who were randomly assigned, t...
Additional file 7: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin t...
Exposure to capsaicin 8% patch (SAS). Bar chart of number of patients by number of capsaicin treatme...
Figure S1. Flow diagram of study selection; Table S1. Primary and secondary endpoints, inclusion and...
Combination therapy as a potential risk factor for the development of type 2 diabetes in patients wi...
Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 5: Figure S3. Risk for cardiovascular and kidney outcome in SGLT2i initiators compar...
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival...
Kaplan-Meier (KM) curves for crude all-cause death rates, macrovascular event rates and T2DM-related...
Kaplan-Meier (KM) curves for crude all-cause death rates, macrovascular event rates and T2DM-related...
Distribution of propensity scores as calculated by logistic regression for MET/SU monotherapy users....
Multivariable Cox regression models estimating time to event for four outcome categories (MET/SU mon...
Additional file 1: Table S1. Descriptive statistics for each drug and dose amount at index date in e...
Additional file 6: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Flow diagram of participants. Chart showing the number of participants who were randomly assigned, t...
Additional file 7: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin t...
Exposure to capsaicin 8% patch (SAS). Bar chart of number of patients by number of capsaicin treatme...
Figure S1. Flow diagram of study selection; Table S1. Primary and secondary endpoints, inclusion and...
Combination therapy as a potential risk factor for the development of type 2 diabetes in patients wi...
Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 5: Figure S3. Risk for cardiovascular and kidney outcome in SGLT2i initiators compar...
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival...